Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

PTX-200 and Carboplatin in Ovarian Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2016 by Prescient Therapeutics, Ltd.
Sponsor:
Information provided by (Responsible Party):
Prescient Therapeutics, Ltd.
ClinicalTrials.gov Identifier:
NCT01690468
First received: September 19, 2012
Last updated: September 7, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2017
  Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)